COMPASS THERAPEUTICS, INC.
80 Guest Street
Suite 601
Boston, Massachusetts 02135
January 17, 2023
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
| Re: | Withdrawal of Acceleration Request—Compass Therapeutics, Inc.: Registration Statement on |
Form S-3 filed December 2, 2022 (File No. 333-268652)
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on January 13, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Tuesday, January 17, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this request for withdrawal, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.
| Sincerely, |
| Compass Therapeutics, Inc. |
| /s/ Vered Bisker-Leib |
| Vered Bisker-Leib |
| President and Chief Operating Officer |
| cc: | Vered Bisker-Leib, Compass Therapeutics, Inc. |
Jonathan Anderman, Compass Therapeutics, Inc.
Richard Hoffman, Esq., Goodwin Procter LLP
James Xu, Esq., Goodwin Procter LLP